Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer
Completed
Conditions studied: Prostate Cancer
In brief
This study will primarily compare the effectiveness of surgery and radiation for localized prostate cancer, the most common male cancer. It will focus on modern technologies and control for differences in patients and treatments that may affect both cancer-related and patient-reported outcomes (such as impotence and incontinence). By figuring out what treatments "work best, in which patients and in whose hands", it will help men with prostate cancer make better decisions regarding their care.
Key facts
- Study ID
- NCT01326286
- Run by
- Vanderbilt University
- People needed
- 3265
- Starts
- 2011-03-01
- Expected to finish
- 2018-09-01
- Last updated by the study team
- 2018-09-26
Who can join
Age: 18 and older, up to 79. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Pathologic diagnosis of adenocarcinoma of the prostate
- Clinically localized stage
- PSA <50ng/ml
- age 18-79
You may not qualify if…
- diagnosis of other malignancy (excluding squamous or basal cell carcinoma of the skin) within 3 years of diagnosis of prostate cancer
- age 80 or greater
- clinically locally advanced or metastatic disease
- PSA equal to or greater than 50 ng/ml
- pathologic diagnosis of prostate cancer greater than 6 months prior to baseline recruitment interview
Where it is running
- University of Southern California — Los Angeles, California, United States
- University of California, San Francisco — San Francisco, California, United States
- Emory University — Atlanta, Georgia, United States
- Lousiana State University Health Sciences Center- New Orleans — New Orleans, Louisiana, United States
- Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.